Physician profile
Megan E Stauffer
NPI 1407977184
$7,671.12
in general payments reported to CMS, 2019-2025
33 companies · $1,726 in 2025
The $1,726 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $586 · 2021: $1,103 · 2022: $891 · 2023: $1,457 · 2024: $1,556 · 2025: $1,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,717 · Education: $21.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,717.24 |
| Education | $21.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,480.95 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $1,337.82 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Genzyme Corporation | $980.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $494.27 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $433.13 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $316.74 | 2019-2025 | Xolair |
| Octapharma USA, INC. | $252.26 | 2021-2024 | Cutaquig |
| Optinose US, INC. | $248.59 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $245.46 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $211.33 | 2021-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $206.11 | 2020-2025 | Eohilia, Hyqvia |
| Amgen INC. | $186.17 | 2021-2024 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $171.19 | 2025 | Neffy |
| Kaleo, INC. | $163.33 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $123.80 | 2019-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $121.52 | 2024-2025 | Sajazir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.98 | 2021-2022 | |
| Grifols USA, LLC | $83.59 | 2023-2025 | Xembify |
| Teva Pharmaceuticals USA, INC. | $74.59 | 2019-2021 | |
| Genentech, INC. | $67.16 | 2023-2024 | Xolair |
| Alk-Abello, INC | $55.49 | 2021-2022 | |
| Phadia US INC. | $52.57 | 2021-2024 | Immunocap |
| Pharming Healthcare, INC. | $43.72 | 2021-2025 | Ruconest |
| Ionis Pharmaceuticals, INC. | $36.76 | 2025 | Dawnzera |
| Blueprint Medicines Corporation | $35.18 | 2021-2023 | Ayvakit |
| Mylan Specialty L.P. | $29.90 | 2021-2023 | Yupelri |
| Leo Pharma INC. | $23.43 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.42 | 2022 | |
| Hologic Sales and Service, LLC | $16.28 | 2023 | Aptima |
| Uswm, LLC | $16.00 | 2021 | |
| Hikma Pharmaceuticals USA | $15.11 | 2023 | Ryaltris |
| Tersera Therapeutics LLC | $14.30 | 2025 | Quzyttir |
| Eyevance Pharmaceuticals LLC | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Stauffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.